16th Open Scientific EIP Symposium on Immunogenicity of Biopharmaceuticals

24th — 26th February 2025

Lisbon, Portugal

Symposium sponsors

We look forward to seeing you in Lisbon for another great conference.

Registration prices

	Members	Non members	Academics
Symposium & Workshop	900€	1,200€	900€
Conference only	700€	1,100€	700€
Workshop only	390€	390€	390€

All prices include 23% VAT.
The EIP Board invites you to be our guest at the social event. If you wish to attend, please ensure that you select this option when booking. Upon confirmation of attendance to the social event, please note that in case of no show a fee of 100.00€ will be charged to cover the costs incurred by EIP.

Click to Register

Deadline for registration

14th February 2025

Sponsoring opportunities

Our annual symposium is the perfect place for your organisation to promote your products and services to an audience of scientific experts active in the area of immunogenicity. The sponsor package includes:

a booth at the conference hotel
a free page in the brochure containing the conference agenda
your logo on the sponsor page of the program
your logo on the conference page of the EIP website
free entrance to the meeting for 2 delegates from your company
full access to the conference including the scientific presentations
two free invitations to the social event

Package prices:

for members of the European Immunogenicity Platform: 10,000 €
for non-members of the European Immunogenicity Platform: 14,000 €

Please email Barbara Vercruyssen if you wish to sponsor the event

After registering as a sponsor, you will receive an invoice. Upon settlement of this invoice, the sponsoring is accepted.

The next step is then to provide us with:

Your company details and contact person’s name, phone number and email address
A visual (photo/image/logo) from your organisation
The URL of your website
An optional YouTube embed URL

Deadline logo and text of your company to be put on EIP website: January 15, 2025
Deadline booth material at Altis Grand Hotel: February 1, 2025
Material needs to be shipped to:
EIP - Altis Grand Hotel, Rua Barata Salgueiro 50, 1250-096 Lisboa, Portugal
For the attention of: Claudia
Conference: EIP, 24^th—26^th February 2025 (contact: Barbara Vercruyssen)

The deadline for sponsoring is 1st February 2025

Download the Sponsoring pack for full details and an application form

Program

Download the program as a PDF

NOTE: Preliminary program published 27/11/2024, potentially subject to change.

Monday, February 24 th 2025
Workshop Day
09:00		Coming Together
09:15		Challenging the current paradigms for clinical immunogenicity testing – the pros and cons Daniel Kramer, Sanofi Arno Kromminga, BioNTech Sebastian Spindeldreher, Integrated Biologix Christopher Tiedje, BioAgilytix Lydia Michaut, Novartis
10:15		Coffee Break
10:45		Continue “Challenging the current paradigms for clinical immunogenicity testing the pros and cons”
12:15		Lunch
13:30		Bring Your own Problems (Break out Sessions) Daniel Kramer, Sanofi Arno Kromminga, BioNTech Sebastian Spindeldreher, Integrated Biologix Sofie Pattijn, IQVIA Noel Smith, Lonza Sophie Tourdot, Pfizer Tim Hickling, Roche ydia Michaut, Novartis
15:00		Coffee Break
15:30		Continue “Bring Your own Problems (Break out Sessions)”
16:30		Closing of the Workshop Day
17:00	18:30	Meeting of the EIP Working Groups Members of EIP working groups

Tuesday, February 25th 2025
09:00		Welcome and Introduction by the EIP Chairman Daniel Kramer, Sanofi
09:15		Spotlight Presentations: Topic to be confimred Speaker to be confirmed

Session 2: Prediction of Immunogenicity Chair: Sebastian Spindeldreher
10:15		EIP NCIRA Working Group Update Sebastian Spindeldreher, Integrated Biologix on behalf of EIP
10:30		Analyzing and decreasing the immunogenicity potential of biotherapeutics using in silico approaches Michael Gutknecht, Novartis - invited
11:00		Coffee Break
11:30		Enhancing Large Molecule Design by Early Integration of MAPPs using Defined Allele Antigen Presenting Cells Andreas Hollenstein, Roche
12:00		The localization of T-cell epitopes in biopharmaceuticals: from peptides to gene therapy vectors Bernard Maillere, University Paris-Saclay
12:30		Lunch Break
13:30		Internalization of therapeutic antibodies into Dendritic cells as a risk factor for immunogenicity Michel Siegel, Roche
14:00		Aggregation of therapeutic antibodies enhances dendritic cell uptake and T-cell responses Marc Pallardy, INSERM
14:30		Suitable peptide controls for screening generic peptide products in adaptive immunogenicity assays Chloë Ackaert, IQVIA - invited
15:00		Coffee Break

Session 3: Immunogenicity Assays Chair: Arno Kromminga
15:30		EIP Immunogenicity Assays Working Group Update Linlin Luo, Merck Sharp & Dome on behalf of EIP
15:45		Current industry practices for in-study cut point setting for clinical immunogenicity assays Riejanne Bax-Seigers, Icon
16:15		Comparing Signal-to-Noise with titer results – a retrospective analysis Karin Benstein, Sanofi
16:45		Addressing Target Interference During the Development of a Neutralizing Anti-Drug Antibody Assay for the clinical support of a bispecific therapeutic antibody Saskia van der Lee, Genmab

Session 3: Social Event Chair: Barbara Vercruyssen
18:00		Get Together
23:00		Good Night

Wedneday, February 26th 2024
Session 4: Immunogenicity Assays continued Chair: Arno Kromminga
09:00		Fit-for-purpose non-clinical immunogenicity assessment to support PK data interpretation – a case study Christopher Tiedje, BioAgilytix
09:30		Evaluating and Mitigating Pre-existing Anti-Drug Antibodies of Bi-Specific Therapeutic Proteins in Early Drug Discovery: A Roche Case Study Janine Faigle, Roche
Short Talks (15 min)
	10:00	A retrospective analysis of clinical immunogenicity data – time for singlicate change Sandra Ribes Miravet, Sandoz Deutschland/Hexal AG - invited
	10:15	Is ADA-tiered approach suitable to therapeutics with pre-existing antibodies? Issa Jyamubandi, Intertek
10:30		Coffee Break
	11:00	Generation of anti-drug antibody (ADA) positive control and development of a bridging immunogenicity assay for RNA therapeutics in human serum Oli Gnana Rajaraman, AiCuris Anti-infective Cures AG
	11:15	Application of SPR technology for assessment of immunogenicity of a dual-peptide cancer vaccine Daniel Worms, BioAgilytix
	11:30	In-depth characterization and semi-quantification of ADAs using innovative hybrid LC-MS methods to support clinical development of biotherapeutics Stephane Muccio, Sanofi

Session 5: Clinical Relevance of Immunogenicity Chair: Lydia Michaut
11:45		Analysis of Clinical Immunogenicity Data for a Multi-Study Program Susan Irvin, Regeneron
12:15		The effects of the immune modulator methotrexate on anti-drug antibody formation Karin Bloem, Sanquin
12:45		Lunch Break
13:45		An American Association of Pharmaceutical Scientists (AAPS) Perspective on Clinical Relevance of Immunogenicity Mohsen Rajabi, Novartis (on behalf of AAPS)

Session 5: Immunogenicity of Novel Modalities Chair: Noel Smith
14:15		The successes in treatment of cancer patients with immunotherapies including T-cell chimeric antigen receptor T-cells (CAR-T) Amy Rosenberg, Epivax
14:45		Exploring alternatives to the 3-tiered immunogenicity testing paradigm for gene therapy programs Robert Nelson, BioAgilytix

Session 6: Regulatory Chair: Daniel Kramer
15:15		Applying Innate immune response modulating impurities testing for immunogenicity risk assessments: Statistical and regulatory considerations Daniela Verthelyi, FDA
15:45		*Topic to be confirmed* Speaker to be confirmed
16:15		Conference Summary & Outlook by the EIP Chairman Daniel Kramer, Sanofi
16:30		Close of the conference

Hotel accommodation

Altis Grand Hotel

The conference venue. Special rates have been negotiated for conference attendees. Please book via the special EIP link for these rates to be applied.

Address

Rua Castilho 11
1269-072 Lisboa
Portugal

Phone

+351 21 310 6000

reservations@altishotels.com

Book now